The BioBasque cluster was established in 2001 with the goal of developing a new life sciences industry in the Basque Country through knowledge generation, business development, and sector dynamization. It has grown to include over 60 companies employing over 1,600 people in R&D and generating over 300 million euros in revenue annually. Many of the companies specialize in areas like diagnostics, therapeutics, drug development, and medical devices. The cluster's success demonstrates that targeted investment in science-based industry can drive productive transformation and economic growth in a region.

1. BioBasque and the Basque BioCluster
Cristina Oyón
Breakout Session: Clusters and smart specialisation strategies: design and
implementation
5 September 2013

3. From the different theoretical ways
of smart diversification, could the
radical foundation of a science
based new industrial activity be a
sound lever for productive
transformation?
Source: The Basque Country Competitiveness Report, 2013 - Orkestra
The Question

5. The BioRegion

6. The Strategy
• First strategy specifically designed (2001-2002) to promote life
sciences in Spain
• Aim: to develop a new business sector in the Basque Country
reated to biosciences
• Integrated approach built around three axis: knowledge
generation, business development, dynamisation
• Mission: to establish a biocluster capable of competing
internationall
• Cuantitative objectives: 40 new companies, 3.000 new jobs
• Chosen as RegioStars 2011 Awards (EU) finalist, among 66
initiatives from 18 countries, awards to most innovative
regional projects which have received funding from the EU
regional/ cohesion policy

7. The Ecosystem

8. The Research Subsystem
Micro-nano-bio convergence

9. The Research Subsystem
The Molecular Imaging Facility

10. The Health Subsystem

11. The Health Subsystem
DEMOTEK: medical
devices effectiveness
demonstration unit

12. The Innovation
Support
Subsystem

13. The Technology Transfer
Process

14. The Business Evolution
now
2001

15. The Government Support
Source: The Basque Country Competitiveness Report, 2013 - Orkestra

16. The Budget
Rough figures of public
investment in 2012
Knowledge
generation
~20 M€
Sector dynamisation
~0,5 M€
Business
development
~5 M€

17. The Outcome

18. 18
Service Provision
Diagnostics
Therapeutics
Other
Antigens, antibodies one-stop shop
Early drug discovery in-vivo
Food, environmental safetyDrug development services
Drug screening & analysis
Clean labs, bio-safety
Engineers and consultants agri-food
Bromatology lab
Drug production support
Ophthalmological sanitary products
Polymeric dispersion µ-beads
Bio-software systems
Natural chem. fungicides (crops)
Cell-based assays (drug discovery)
Metabolomic Dx
Vaccines, allergology
Drug development (CNS)
Regenerative medicine
Full-cycle Pharma
Tissue engineering, cell therapy
Biotech cosmetics
Nanomedicines (biocompatible nanoparticles)
Drug development, distribution
Non-invasive Dx (ophthalmology )
Genetic Dx methods
Genomic IVD tests
In-vitro Dx tests Dx & Tp animal health
The Outcome

19. The Outcome
BioBasque is recognized as a BioRegion at national and
international scale. We are the 4th community in Spain
regarding nr of biotechs, accounting for the 9%, well above
the 6% of Spanish GDP that supposes the Basque economy.
In 2007-2011 the nr of biotechs has been multiplied by 1,4.
The sector employs directly 1.600 persons in R&D,
representing 5,8% of total employment in R&D. The R&D
personnel accounts for the 50% of total employment
The sector invoices more than 300 M€. 57% of biotechs have
increased its invoicing in the period 2007-2011. 31% have
maintained it.
60% of biotechs are less than 10 years old. 90% of them are
internationalized

20. The Future
TRANSVERSAL CAPACITIES
• Biosciences
• Nanosciences
• Advanced manufacturing
MARKETS
• Movility & Transport
• Digital World
• Science Industry
• Ageing / Health
• Energy
Bio-Nano
Sciences
Smart
Manufacturing
Energy
EXISTING
PRIORIZITATION
(PCTI 2015)
REFLECTION
PROCESS
META
PRIORITIES
REFLECTION
PROCESS
PILOT
PROJECTS
Source: The Basque Country Competitiveness Report, 2013 - Orkestra

21. Cristina Oyón
Head of Strategic Initiatives, SPRI
cristina@spri.es
biobasque@spri.es
www.biobasque.org